Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 211 to 222 of 222 results for physical activity older people

  1. Galcanezumab for preventing migraine (TA659)

    Evidence-based recommendations on galcanezumab (Emgality) for preventing migraine in adults.

    Technology appraisal guidance
    Published
    18 November 2020
    View recommendations

    Sections for TA659

  2. 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (TA1045)

    Evidence-based recommendations on 12 standard quality house dust mite sublingual lyophilisate (SQ-HDM SLIT; Acarizax) for treating allergic rhinitis and allergic asthma caused by house dust mites.

    Technology appraisal guidance
    Published
    5 March 2025
    View recommendations

    Sections for TA1045

  3. Spesolimab for treating generalised pustular psoriasis flares (TA1070)

    Evidence-based recommendations on spesolimab (Spevigo) for treating generalised pustular psoriasis flares in adults.

    Technology appraisal guidance
    Published
    18 June 2025
    View recommendations

    Sections for TA1070

  4. Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms (TA934)

    Evidence-based recommendations on foslevodopa–foscarbidopa (Produodopa) for treating advanced Parkinson’s with motor symptoms in adults.

    Technology appraisal guidance
    Published
    29 November 2023
    View recommendations

    Sections for TA934

  5. Fremanezumab for preventing migraine (TA764)

    Evidence-based recommendations on fremanezumab (Ajovy) for preventing migraine in adults.

    Technology appraisal guidance
    Published
    2 February 2022
    View recommendations

    Sections for TA764

  6. Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)

    Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making

    Evidence summary
    Published
    2 December 2015

  7. Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (TA992)

    Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for HER2-low metastatic or unresectable breast cancer after chemotherapy in adults.

    Technology appraisal guidance
    Published
    29 July 2024
    View recommendations

    Sections for TA992

  8. Artificial intelligence (AI)-derived software to help clinical decision making in stroke (HTG708)

    Evidence-based recommendations on artificial intelligence-derived software to help clinical decision making in stroke.

    HealthTech guidance
    Last updated
    2 May 2024
    View recommendations

    Sections for HTG708

  9. High-sensitivity troponin tests for the early rule out of NSTEMI (HTG552)

    Evidence-based recommendations on high-sensitivity troponin tests for the early rule out of NSTEMI (non-ST-segment elevation myocardial infarction).

    HealthTech guidance
    Published
    26 August 2020
    View recommendations

    Sections for HTG552

  10. ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot (MIB56)

    NICE has developed a medtech innovation briefing (MIB) on the ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot

    Medtech innovation briefing
    Published
    11 March 2016

  11. Mobi-C for cervical disc replacement (MIB70)

    NICE has developed a medtech innovation briefing (MIB) on Mobi-C for cervical disc replacement

    Medtech innovation briefing
    Published
    28 June 2016

  12. LARS for reconstructing damaged intra-articular cruciate knee ligaments (MIB30)

    NICE has developed a medtech innovation briefing (MIB) on LARS for reconstructing damaged intra-articular cruciate knee ligaments

    Medtech innovation briefing
    Published
    22 May 2015